Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsTheresa J. Goletz, Jay A. Berzofsky, Lee J. Helman
Life of this patent
Estimating the term…
Abstract
A method of immunizing a mammal against a tumor cell by exposing splenic or peripheral blood mononuclear cells to a peptide that encompasses a fusion joint of a fusion protein encoded by DNA spanning a human chromosomal translocation associated with Ewing's sarcoma (t(11;22)(q24;q12)) or alveolar rhabdomyosarcoma (t(2:13)(q35;q14)) is provided.
Claims22
A method for immunization, which comprises:
- (i) exposing splenic or peripheral blood mononuclear cells to a peptide, whereby said peptide has a length of at least 9 amino acids and binds to MHC class I molecules on the surface of said mononuclear cells, and wherein said peptide has an amino acid sequence that encompasses the fusion joint of a Ewing's sarcoma (ES)-associated tumor-specific fusion protein encoded by a human chromosomal t(11;22)(q24;q12) translocation or that encompasses the fusion joint of an Alveolar Rhabdomyosarcoma (ARMS) tumor-specific fusion protein encoded by a human chromosomal t(2;3)(q35;q14) translocation;
- (ii) irradiating said mononuclear cells having said peptide bound to MHC class I molecules on their surface;
- and
- (iii) administering to a mammal the irradiated mononuclear cells having said peptide bound to MHC class I molecules on the their surface.
An immunogen which comprises a population of peripheral blood mononuclear cells coated with a peptide having a length of at least 9 amino acids, which is bound to MHC class I molecules on the surface of said mononuclear cells, wherein said peptide has an amino acid sequence that encompasses the fusion joint of an Ewing's sarcoma (ES)-associated tumor-specific fusion protein encoded by a human chromosomal t(11;22)(q24;q12) translocation or that encompasses the fusion joint of an Alveolar Rhabdomyosarcoma (ARMS)-associated tumor-specific fusion protein encoded by a human chromosomal t(2;3)(q35;q14) translocation, and a pharmaceutically acceptable carrier.
A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:6, 7, 8. 9, and 10.
A pharmaceutical composition comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:6, 7, 8, 9, and 10, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.